Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29804846 | 0.94 | SLC17A5 (0.54) | SLC17A5TDP1ALDH1A1HPGDKDM4E | |
| SCHEMBL29829450 | 0.94 | SLC17A5 (0.54) | SLC17A5TDP1ALDH1A1HPGDKDM4E | |
| SCHEMBL12480413 | 0.85 | SLC17A5 (0.58) | SLC17A5TDP1ALDH1A1HPGDKDM4E | |
| SCHEMBL19927329 | 0.83 | CASP3 (0.48) | NPC1KMT2ACASP3 | |
| SCHEMBL19927331 | 0.83 | CASP3 (0.48) | NPC1KMT2ACASP3 | |
| Galnon SCHEMBL4464884 | 0.79 | TLR2 (0.44) | SLC17A5TDP1ALDH1A1HPGDKDM4E | |
| Galnon SCHEMBL6834012 | 0.79 | TLR2 (0.44) | SLC17A5TDP1ALDH1A1HPGDKDM4E | |
| SCHEMBL1575122 | 0.79 | SLC17A5 (0.55) | SLC17A5TDP1ALDH1A1HPGDKDM4E | |
| SCHEMBL16294412 | 0.78 | CASP3 (0.59) | KMT2ACASP3 | |
| SCHEMBL16294410 | 0.78 | CASP3 (0.59) | KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509502-B2 | Hybrid immunoglobulin containing nonpeptidyl linkage | BIOMOLECULAR HOLDINGS LLC (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4169944-A1 | PROCESS FOR PREPARING HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | Biomolecular Holdings LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20220275108-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC (US) | 2022-09-01 | — | — | US | disclosed |
| EP-4039281-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | Biomolecular Holdings LLC (US) | 2022-08-10 | — | — | EP | disclosed |
| EP-3701971-B1 | COMPOUNDS USEFUL IN PREPARING HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC (US) | 2022-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275108-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | FCGR3B, FCGR2A, VSIG8 | SLC17A5 795/4885TDP1 4237/4885ALDH1A1 4665/4885 |
| US-12509502-B2 | Hybrid immunoglobulin containing nonpeptidyl linkage | FCGR2A, FCGR3B, CD74 | SLC17A5 635/4885TDP1 4675/4885ALDH1A1 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.